Case Western, Picture Health partner to develop AI tools for lung cancer

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Tumor-infiltrating clonal hematopoiesis is prevalent across solid tumors with the highest incidence in non-small cell lung cancer and results in a higher rate of mortality, according to a study by Caris Life Sciences that independently validates recent findings on TI-CH.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.

July 25, 2025

Vol.51 No.29

Drugs & Targets

FDA grants Breakthrough Therapy designation to elironrasib for lung cancer

FDA granted Breakthrough Therapy designation to elironrasib, a RAS(ON) G12C-selective inhibitor, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.

July 25, 2025

Vol.51 No.29

Imaging’s ride to the bottom in clinical trials—and why it matters now

In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.

ACR to launch artificial intelligence economics committee

The American College of Radiology is launching a new Artificial Intelligence Economics Committee to help consolidate available resources and develop financial strategies to address development and deployment of radiologic AI tools.

July 18, 2025

Vol.51 No.28

Case Western, Picture Health partner to develop AI tools for lung cancer

YOU MAY BE INTERESTED IN

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

FDA grants Breakthrough Therapy designation to elironrasib for lung cancer

Imaging’s ride to the bottom in clinical trials—and why it matters now

ACR to launch artificial intelligence economics committee

Renew today!

Subscriber content

Never miss an issue!

Login